Compound dossier · evidence, sources, and live market
Semaglutide
GLP-1 agonist Strong evidence 3 cited studies 27 live vendors
Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1) hormone, primarily studied in research for its effects on glucose metabolism and appetite regulation. This peptide is commonly investigated in laboratory settings for its potential in metabolic and obesity-related research models.
Evidence brief
Semaglutide is a GLP-1 receptor agonist studied in phase 3 randomized controlled trials and summarized in a meta-analysis for weight management and type 2 diabetes.
first-party prices captured 37m ago
Compare by exact vialThe small sealed glass container a compound ships in. size: 5mg (18 vendors)10mg (22 vendors)20mg (9 vendors)30mg (11 vendors)50mg (3 vendors)
Approved by the FDA (Ozempic, Wegovy, Rybelsus), EMA, and MHRA for type-2 diabetes and obesity.Research use only — not medical advice.
These figures are what pepmg still publishes about price: the floor, the middle, the spread and how many sources we track, computed from listings we captured first-party and refreshed on the same schedule as always. We no longer publish the individual listings or the sellers behind them.
Computed from 69 in-stock listings across 27 sources we captured first-party, with bulk vials, blends and statistical outliers excluded so the figures compare like with like. The spread is the highest tracked price divided by the lowest — how much the same milligram varies depending on where you look. The chart is the daily minimum; days we did not capture are left out rather than filled in.
- What the research says about semaglutide Strong evidence
Semaglutide is a GLP-1 receptor agonist studied in phase 3 randomized controlled trials and summarized in a meta-analysis for weight management and type 2 diabetes.
Read the full review → - Are research peptides safe? What the evidence does and doesn't show Limited evidence
"Are peptides safe?" has no single answer. The compounds sold as research peptides sit at very different points on the evidence scale, from large randomized human trials for a few to animal-only data for many.
Read the full review →
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial PubMed ↗
This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2.4 mg versus semaglutide 1.0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight…
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis PubMed ↗
The weight loss benefit of semaglutide in patients with diabetes is well-documented, but its clinical utility in treating obesity among patients without diabetes is less described. We therefore assessed the efficacy and safety of…
- Safety of Semaglutide PubMed ↗
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively…
A few representative studies, each summarized on this site with the PubMed record linked beside it — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. Everything here is research use only.
▸ Why compare $/mg for Semaglutide?
Per-mg prices for semaglutide vary significantly across vendors due to differences in synthesis purity, scale, and sourcing of raw materials. Comparing prices helps researchers identify cost-effective suppliers while maintaining quality standards for reproducible experimental results.
▸ Reading the COA
A third-party Certificate of Analysis (COA) for semaglutide should confirm identity via mass spectrometry (e.g., ESI-MS) and purity ≥98% by HPLC. Common issues include under-filling (e.g., actual content below labeled mg/vial) and adulteration with truncated or oxidized peptide fragments.
▸ FAQ
▸ Same cluster
| Retatrutide | $2.02/mg | vs Semaglutide → |
| Tirzepatide | $1.35/mg | vs Semaglutide → |
| Cagrilintide | $4.60/mg | vs Semaglutide → |
| AOD-9604 | $4.00/mg | vs Semaglutide → |
| HGH Frag 176-191 | $5.73/mg | vs Semaglutide → |
| 5-Amino-1MQ | $0.80/mg | vs Semaglutide → |
| Survodutide | $7.39/mg | vs Semaglutide → |
| Mazdutide | $5.72/mg | vs Semaglutide → |
| Teduglutide | $2.37/mg | |
| Orforglipron | $21.50/mg | vs Semaglutide → |
| Tesofensine | $159.98/mg | vs Semaglutide → |
| SLU-PP-332 | $3.33/mg | vs Semaglutide → |
| BAM15 | $1.96/mg | vs Semaglutide → |
| AICAR | $0.63/mg | vs Semaglutide → |
| Adipotide | $7.60/mg | vs Semaglutide → |
| L-Carnitine | $9.90/mg |